SAGIMET BIOSCIENCES INC-A (SGMT) Stock Price & Overview
NASDAQ:SGMT • US7867001049
Current stock price
The current stock price of SGMT is 5.42 USD. Today SGMT is up by 2.26%. In the past month the price increased by 4.03%. In the past year, price increased by 145.25%.
SGMT Key Statistics
- Market Cap
- 176.638M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.57
- Dividend Yield
- N/A
SGMT Stock Performance
SGMT Stock Chart
SGMT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SGMT. When comparing the yearly performance of all stocks, SGMT is one of the better performing stocks in the market, outperforming 92.64% of all stocks.
SGMT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SGMT. No worries on liquidiy or solvency for SGMT as it has an excellent financial health rating, but there are worries on the profitability.
SGMT Earnings
SGMT Forecast & Estimates
18 analysts have analysed SGMT and the average price target is 25.96 USD. This implies a price increase of 379.04% is expected in the next year compared to the current price of 5.42.
SGMT Groups
Sector & Classification
SGMT Financial Highlights
Over the last trailing twelve months SGMT reported a non-GAAP Earnings per Share(EPS) of -1.57. The EPS decreased by -9.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.91% | ||
| ROE | -48.36% | ||
| Debt/Equity | 0 |
SGMT Ownership
SGMT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 367.796B | ||
| AMGN | AMGEN INC | 15.32 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.94 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.34 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SGMT
Company Profile
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in San Mateo, California and currently employs 16 full-time employees. The company went IPO on 2023-07-14. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The firm is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
Company Info
IPO: 2023-07-14
SAGIMET BIOSCIENCES INC-A
155 Bovet Rd., Suite 303
San Mateo CALIFORNIA US
Employees: 16
Phone: 16505618600
SAGIMET BIOSCIENCES INC-A / SGMT FAQ
What does SAGIMET BIOSCIENCES INC-A do?
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in San Mateo, California and currently employs 16 full-time employees. The company went IPO on 2023-07-14. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The firm is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
Can you provide the latest stock price for SAGIMET BIOSCIENCES INC-A?
The current stock price of SGMT is 5.42 USD. The price increased by 2.26% in the last trading session.
Does SGMT stock pay dividends?
SGMT does not pay a dividend.
What is the ChartMill rating of SAGIMET BIOSCIENCES INC-A stock?
SGMT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for SGMT stock?
18 analysts have analysed SGMT and the average price target is 25.96 USD. This implies a price increase of 379.04% is expected in the next year compared to the current price of 5.42.
Can you provide the upcoming earnings date for SAGIMET BIOSCIENCES INC-A?
SAGIMET BIOSCIENCES INC-A (SGMT) will report earnings on 2026-05-11, before the market open.